Oropharyngeal candidiasis in the era of antiretroviral therapy.
Oropharyngeal candidiasis (OPC) remains a common problem in the HIV-infected population despite the availability of antiretroviral therapy (ART). Although Candida albicans is the most frequently implicated pathogen, other Candida species also may cause infection. The emergence of antifungal resistance within these causative yeasts, especially in patients with recurrent oropharyngeal infection or with long-term use of antifungal therapies, requires a working knowledge of alternative antifungal agents. Identification of the infecting organism and antifungal susceptibility testing enhances the ability of clinicians to prescribe appropriate antifungal therapy. Characterization of the responsible mechanisms has improved our understanding of the development of antifungal resistance and could enhance the management of these infections. Immune reconstitution has been shown to reduce rates of OPC, but few studies have evaluated the current impact of ART on the epidemiology of OPC and antifungal resistance in these patients. Preliminary results from an ongoing clinical study showed that in patients with advanced AIDS, oral yeast colonization was extensive, occurring in 81.1% of the 122 patients studied, and symptomatic infection occurred in one-third. In addition, resistant yeasts were still common, occurring in 25.3% of patients colonized with yeasts or with symptomatic infection. Thus, OPC remains a significant infection in advanced AIDS, even with ART. Current knowledge of the epidemiology, pathogenesis, clinical presentation, treatment, and mechanisms of antifungal resistance observed in OPC are important in managing patients with this infection and are the focus of this review.
Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA. thompsong2@uthscsa.edu
George R
GR
Thompson
Payal K
PK
Patel
William R
WR
Kirkpatrick
Steven D
SD
Westbrook
Deborah
D
Berg
Josh
J
Erlandsen
Spencer W
SW
Redding
Thomas F
TF
Patterson
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000145:classification / Q000627:therapeutic use; D002175:Candida / Q000145:classification / Q000187:drug effects; D002180:Candidiasis, Oral / Q000175:diagnosis*; D025141:Drug Resistance, Fungal; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D009960:Oropharynx / Q000382:microbiology*; D010608:Pharyngeal Diseases / Q000382:microbiology*
D044966:Anti-Retroviral Agents; D000935:Antifungal Agents